reference standard is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-09. Numbers and descriptions here follow the published literature rather than marketing material.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
UDP + procollagen 5-(D-galactosyloxy)-L-lysine Thus, the two substrates of this enzyme are UDP-galactose and procollagen 5-hydroxy-L-lysine, whereas its two products are UDP and procollagen 5-(D-galactosyloxy)-L-lysine.
Like most KWS institute directors, Haber had accrued a large discretionary fund. It was his wish that it be distributed to the dismissed staff to facilitate their emigration. Hahn brokered a deal whereby 10 per cent of the funds would be allocated to Haber's people and the rest to KWS, but the Rockefeller Foundation insisted that the funds be used for their original scientific research or else be returned. In August 1933 the administrators of the KWS were alerted that several boxes of Rockefeller Foundation-funded equipment were about to be shipped to Herbert Freundlich, one of the department heads that Hahn had dismissed, who was now working in England. Ernst Telschow, a Nazi Party member, was in charge while Planck, the president of the KWS since 1930, was on vacation, and he ordered the shipment halted. Hahn complied, but he disagreed with the decision on the grounds that funds from abroad should not be diverted to military research, which the KWS was increasingly undertaking. When Planck returned from vacation, he ordered Hahn to expedite the shipment. Haber died on 29 January 1934. A memorial service was held on the first anniversary of his death. University professors were forbidden to attend, so they sent their wives in their place. Hahn, Planck and Joseph Koeth attended, and gave speeches. The ageing Planck did not seek re-election, and was succeeded in 1937 as president by Carl Bosch, a winner of the Nobel Prize in Chemistry and the chairman of the board of IG Farben, a company which had bankrolled the Nazi Party since 1932. Telschow became Secretary of the KWS.
Rapid and simple – simple contact for 10–120 minutes and constructs spontaneously and stably incorporate – no washing required. Replicable – same variables (time, temperature, concentration) equals the same result. Toxicity – FSL constructs are biocompatible, disperse into biological solutions without solvents, detergents. They label non-covalently and are non-genetic. Normal vitality and functionality is maintained in modified cells/virions/organisms. Toxicity/vitality experiments in small laboratory animals, zebrafish, cell cultures, spermatozoa and embryos find no toxic effects within physiological ranges. Amphiphilic – the amphiphilic nature of the FSL Kode construct makes them water dispersible (clear solution of micelles), yet once interacted with a membrane they insert/coat and become water resistant Variable design – a single F can be presented in more than 100 ways by varying the spacer and lipid. High biovisibility – as the spacer holds the F moiety away for the membrane it is able to achieve increased sensitivity, specificity and reactivity can be optimized by use of multiple and variable biomarker presentations on the same surface. Additive – FSL modification is compatible with other technologies allowing users to add additional features to cells/viruses/organisms/surfaces already modified by more traditional methods. Multiple FSL constructs may be added to a surface simultaneously by simply creating a mix of FSL Kode constructs. Constructs insert into living or fixed cell (glutaraldehyde) membranes.
== Use and effects == A phase 1 dose-ranging clinical trial found that zalsupindole is non-hallucinogenic in humans across a dose range of 2 to 360 mg orally. Nonetheless, it produced changes in brain function as measured by quantitative electroencephalography (qEEG).
Sources: en.wikipedia.org
=== Health and safety === The resins used to create OSB have raised questions about their emission of volatile organic compounds such as formaldehyde, although industry trade groups assert that formaldehyde emissions from North American OSB are "negligible or nonexistent". Urea-formaldehyde is more toxic and should be avoided in home use. Phenol-formaldehyde products are considered to be relatively hazard free. Some newer types of OSB, so-called "new-generation" panels, use isocyanate resins that contain no formaldehyde and are considered nonvolatile when cured. Some manufacturers treat the wood chips with various borate compounds that are toxic to termites, wood-boring beetles, molds, and fungi, but not mammals in applied doses. In 2024, a hotel in Dublin, Ireland, lost its fire safety certificate after an inspection found fault with the composition of OSB in its flooring and walls.
== Clinical signs == Many signs are associated with PPID, but only a subset of these is displayed in any single horse. Some horses may present with chronic laminitis without other overt signs of the disease.
==== 16th century ==== The first records relating to the Cossack villages: the "stanitsas", date back to 1549. In the year 1552 Don Cossacks under the command of Ataman Susar Fedorov joined the Army of Ivan the Terrible during the Siege of Kazan in 1552. On 2 June 1556 the Cossack regiment of Ataman Lyapun Filimonov, together with the Army of Moscovits comprising strelets, conquered and annexed the Astrakhan Khanate. During the reign of Ivan the Terrible (Ivan IV), the ataman Yermak Timofeyevich went on an expedition to conquer Siberia. After defeating Khan Kuchum in the fall of 1582 and occupying Isker, the capital of the Siberian Khanate, Yermak sent a force of Cossacks down the Irtysh in the winter of 1583. The detachment, led by Bogdan Bryazga (according to other sources, the Cossack chieftain Nikita Pan) passed through the lands of the Konda-Pelym Voguls and reached the walls of the town of Samarovo. Surprised by the Cossack attack, the Ostyaks surrendered. In the autumn of 1585, shortly after Yermak's death, Cossacks led by voevoda (army commander) Ivan Mansurov founded the first Russian fortified town in Siberia, Obskoy, at the mouth of the Irtysh river on the right bank of the Ob river. The Mansi and Khanty lands thus became part of the Russian state, finally secured by the founding of the cities of Pelym and Berezov in 1592 and Surgut in 1594. As a result of Yermak's expedition, Russia was able to annex Siberia.
Sources: en.wikipedia.org
On the contrary, contrast, drugs that inhibit both MRP3/4 and BSEP (e.g., rifampicin, troglitazone, bosentan) pose greater risk for cholestasis MDR3 is another key canalicular efflux transporter that is the target of inhibition by certain drugs. MDR3 secretes phosphatidylcholine into bile canaliculi, where it form micelles with bile salts to dissolve cholesterol as well as protect hepatocyte and cholangiocytes from damage by bile salts. MDR3 inhibition leads to low phospholipid concentrations in bile that damages cholangiocytes and leads to cholestasis. Antifungal azoles such itraconazole have been shown to inhibit both MDR3 and BSEP, thus giving them higher cholestatic potential. Other MDR3-inhibiting drugs are chlorpromazine, imipramine, haloperidol, ketoconazole, saquinavir, clotrimazole, ritonavir, and troglitazone. Another target for inhibition, MRP2 is an apical efflux transporter that mainly exports bilirubin glucuronide and glutathione into bile. However, MRP2 is also the preferential route of export for certain sulfated conjugated BAs (taurolithocholic acid and glycolithocholic acid), so its inhibition could contribute to cholestasis. On the hepatocyte basolateral membrane, Na+-taurocholate cotransporting peptide (NTCP) is the major transporter of conjugated bile acids. Enterohepatic bile flow requires the concerted activity of both NTCP and BSEP, which form the major route by which BAs enter and exit hepatocytes respectively.
Moscow has a humid continental climate (Köppen climate classification: Dfb) with long, cold winters usually lasting from mid-November to the end of March, along with warm summers. More extreme continental climates at the same latitude—such as parts of Eastern Canada or Siberia—have much colder winters than Moscow does, suggesting that Moscow receives significant moderation from the Atlantic Ocean, even though the city is distant from it. Weather in Moscow can fluctuate widely: in the winter, temperatures range from −25 °C (−13 °F) in the city and −30 °C (−22 °F) in the suburbs to above 5 °C (41 °F); in the summer, temperatures range from 10 to 35 °C (50 to 95 °F).
== Further reading == Kielley WW, Bradley LB (1954). "Glutathione thiolesterase". J. Biol. Chem. 206 (1): 327–33. doi:10.1016/S0021-9258(18)71321-5. PMID 13130552. Murata, Kousaku; Sato, Nobuyuki; Rhee, Hae-ik; Watanabe, Kunihiko; Kimura, Akira (1987). "Purification and Characterization of Glutathione Thiol Esterase from Saccharomyces cerevisiae". Agricultural and Biological Chemistry. 51 (7): 1901–1907. doi:10.1080/00021369.1987.10868321. Uotila, Lasse (1979). "Glutathione thiol esterases of human red blood cells". Biochimica et Biophysica Acta (BBA) - Protein Structure. 580 (2): 277–288. doi:10.1016/0005-2795(79)90140-5. PMID 93000.
=== Synthesis based on hydrogen cyanide === A research project completed in 2015 by John Sutherland and others found that a network of reactions beginning with hydrogen cyanide and hydrogen sulfide, in streams of water irradiated by UV light, could produce the chemical components of proteins and lipids, as well as those of RNA, while not producing a wide range of other compounds. The researchers used the term "cyanosulfidic" to describe this network of reactions.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.